[HTML][HTML] Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …
genomic landscapes and biological functions, the treatment of PCa continues to improve …
[HTML][HTML] Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer
MA Rice, SV Malhotra, T Stoyanova - Frontiers in oncology, 2019 - frontiersin.org
Prostate cancer is the most commonly diagnosed cancer affecting men in the United States.
The prostate is a hormone-dependent gland in which androgen hormones testosterone and …
The prostate is a hormone-dependent gland in which androgen hormones testosterone and …
[HTML][HTML] Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer
W Liu, B Chakraborty, R Safi, D Kazmin… - Nature …, 2021 - nature.com
Hypercholesterolemia and dyslipidemia are associated with an increased risk for many
cancer types and with poor outcomes in patients with established disease. Whereas the …
cancer types and with poor outcomes in patients with established disease. Whereas the …
[HTML][HTML] Role of androgen receptor in prostate cancer: a review
K Fujita, N Nonomura - The world journal of men's health, 2019 - synapse.koreamed.org
Androgen receptor (AR) is a steroid receptor transcriptional factor for testosterone and
dihydrotestosterone consisting of four main domains, the N-terminal domain, DNA-binding …
dihydrotestosterone consisting of four main domains, the N-terminal domain, DNA-binding …
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
PA Watson, VK Arora, CL Sawyers - Nature Reviews Cancer, 2015 - nature.com
During the past 10 years, preclinical studies implicating sustained androgen receptor (AR)
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …
[HTML][HTML] Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications
G Aurilio, A Cimadamore, R Mazzucchelli… - Cells, 2020 - mdpi.com
Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial
diagnosis; hence, androgen ablation therapy directed toward a reduction in serum …
diagnosis; hence, androgen ablation therapy directed toward a reduction in serum …
[HTML][HTML] Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
T Chandrasekar, JC Yang, AC Gao… - … andrology and urology, 2015 - ncbi.nlm.nih.gov
Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …
cancer remains high. Approximately 20% of men present with advanced or metastatic …
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer
R Hu, C Lu, EA Mostaghel, S Yegnasubramanian… - Cancer research, 2012 - AACR
Continued androgen receptor (AR) signaling is an established mechanism underlying
castration-resistant prostate cancer (CRPC), and suppression of androgen receptor …
castration-resistant prostate cancer (CRPC), and suppression of androgen receptor …
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
AA Shafi, AE Yen, NL Weigel - Pharmacology & therapeutics, 2013 - Elsevier
Abstract In the United States, prostate cancer (PCa) is the most commonly diagnosed non-
cutaneous cancer in males and the second leading cause of cancer-related death for men …
cutaneous cancer in males and the second leading cause of cancer-related death for men …
Key role of CRF in the skin stress response system
AT Slominski, MA Zmijewski, B Zbytek… - Endocrine …, 2013 - academic.oup.com
The discovery of corticotropin-releasing factor (CRF) or CRH defining the upper regulatory
arm of the hypothalamic-pituitary-adrenal (HPA) axis, along with the identification of the …
arm of the hypothalamic-pituitary-adrenal (HPA) axis, along with the identification of the …